Therapy News and Research

RSS

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular (“wet”) Age-related Macular Degeneration (AMD).

24 Oct 2011

Six prominent surgeons receive ACS' Honorary Fellowship

Honorary Fellowship in the American College of Surgeons (ACS) was awarded to six prominent surgeons from South Africa, England, Ireland, Italy, The Netherlands, and the People's Republic of China last night during Convocation ceremonies that preceded the official opening of the College's 97th Annual Clinical Congress.

24 Oct 2011

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.

24 Oct 2011

Physical abnormality in airway linked with autism

Autism and autistic spectrum disorders (ASD) are currently diagnosed primarily through subjective observation of autistic behaviors. However, new research, presented at CHEST 2011, the 77th annual meeting of the American College of Chest Physicians (ACCP), suggests that a physical abnormality in the airway may be a prominent indicator for autism and autistic spectrum disorders, making it a possible diagnostic marker for this disease.

24 Oct 2011

Study: Heart transplantation is a very safe and effective therapy

Heart transplantation is a very safe and effective therapy, according to a new long-term study presented today at the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

24 Oct 2011

Children with PAH may benefit from sildenafil treatment

Sildenafil is currently approved for adult pulmonary arterial hypertension (PAH); however, new research presented at CHEST 2011, the 77th annual meeting of the American College of Chest Physicians (ACCP), shows the drug may also provide significant benefits for children with PAH, helping to improve both oxygen delivery and exercise capacity.

24 Oct 2011

Genetically engineered clotting factor shows promise against hemophilia

A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.

24 Oct 2011

Mayo Clinic researchers share latest findings at child and adolescent psychiatry meeting

Mayo Clinic researchers are sharing their latest research findings this week at the American Academy of Child and Adolescent Psychiatry Meeting in Toronto.

22 Oct 2011

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

Today Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial, the first of two registrational studies designed to evaluate the investigational compound daclizumab high-yield process in people with relapsing-remitting multiple sclerosis.

22 Oct 2011

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA (darunavir) tablets to include 192-week data from the ARTEMIS study.

22 Oct 2011

VTT to develop next-generation vaccines against allergy

VTT holds patents on gene technology which can be applied to alter the structure of an allergen, i.e. a protein causing allergy, so that it will cause less allergic symptoms than the original allergen, while remaining effective in desensitisation therapy.

22 Oct 2011

NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns.

22 Oct 2011

Biomarker can help identify GVHD in cancer patients after hematopoietic stem cell transplant

A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.

22 Oct 2011

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.

22 Oct 2011

Blood pressure-lowering medication appears to kick start brain recovery after stroke

A commonly prescribed blood pressure-lowering medication appears to kick start recovery in the unaffected brain hemisphere after a stroke by boosting blood vessel growth, a new University of Georgia study has found.

22 Oct 2011

Reconstructive surgery can delay endoprosthetic joint replacement in patients with OA

Reconstructive surgical approaches can help delay endoprosthetic joint replacement in patients with osteoarthritis. Henning Madry and coauthors introduce such procedures in the current issue of Deutsches Ärzteblatt International.

22 Oct 2011

DFG announces establishment of twelve research units

The Deutsche Forschungsgemeinschaft has established nine new Research Units and three Clinical Research Units. The decision was made by the Joint Committee of Germany's central research funding organisation at its October meeting in Bonn.

22 Oct 2011

Watson receives FDA approval for Androderm lower-dose formulations

Watson Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved its Androderm (testosterone transdermal system) 2 mg and 4 mg formulation.

21 Oct 2011

Study presents state-level data concerning suicidal thoughts and behavior among U.S. adults

Every 15 minutes, someone in the United States dies by suicide. And for every person who dies, there are many more who think about, plan or attempt suicide, according to a report released today by the Centers for Disease Control and Prevention.

21 Oct 2011

RSV medication from specialty pharmacies increases likelihood of children receiving recommended doses

Children given an injectable medication to help prevent severe respiratory illness had a 17.6 percent higher likelihood of receiving the American Academy of Pediatrics (AAP) recommended doses when they were administered through a specialty pharmacy rather than a traditional pharmacy, according to a new study released today by pharmacy benefit manager Prime Therapeutics (Prime).

21 Oct 2011

Therapy News and Research

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Six prominent surgeons receive ACS' Honorary Fellowship

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Physical abnormality in airway linked with autism

Study: Heart transplantation is a very safe and effective therapy

Children with PAH may benefit from sildenafil treatment

Genetically engineered clotting factor shows promise against hemophilia

Mayo Clinic researchers share latest findings at child and adolescent psychiatry meeting

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

Janssen announces FDA label update approval for PREZISTA HIV tablets

VTT to develop next-generation vaccines against allergy

NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis

Biomarker can help identify GVHD in cancer patients after hematopoietic stem cell transplant

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Blood pressure-lowering medication appears to kick start brain recovery after stroke

Reconstructive surgery can delay endoprosthetic joint replacement in patients with OA

DFG announces establishment of twelve research units

Watson receives FDA approval for Androderm lower-dose formulations

Study presents state-level data concerning suicidal thoughts and behavior among U.S. adults

RSV medication from specialty pharmacies increases likelihood of children receiving recommended doses

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News